ESR1 and breast cancer: Further studies are now required to elucidate the potential differential roles of Cav3.2 in different breast cancer subtypes and its utility as a potential biomarker of prognosis and therapeutic responsiveness in patients with ER + and HER2-positive breast cancers respectively.